Suppr超能文献

抗分枝杆菌药物在肺结核细胞模型中调节免疫致病基质金属蛋白酶。

Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis.

作者信息

Singh Shivani, Kubler Andre, Singh Utpal K, Singh Ajay, Gardiner Harriet, Prasad Rajniti, Elkington Paul T, Friedland Jon S

机构信息

Infectious Diseases and Immunity, Imperial College London, London, United Kingdom.

Tuberculosis Unit, Department of Medicine and Paediatrics, Nalanda University Hospitals, Agam Kuan, Patna, India.

出版信息

Antimicrob Agents Chemother. 2014 Aug;58(8):4657-65. doi: 10.1128/AAC.02141-13. Epub 2014 Jun 2.

Abstract

Tuberculosis is characterized by extensive destruction and remodelling of the pulmonary extracellular matrix. Stromal cell-derived matrix metalloproteinases (MMPs) are implicated in this process and may be a target for adjunctive immunotherapy. We hypothesized that MMPs are elevated in bronchoalveolar lavage fluid of tuberculosis patients and that antimycobacterial agents may have a modulatory effect on MMP secretion. Concentrations of MMP-1, -2, -3, -7, -8, and -9 were elevated in the bronchoalveolar lavage fluid from tuberculosis patients compared to those in bronchoalveolar lavage fluid from patients with other pulmonary conditions. There was a positive correlation between MMP-3, MMP-7, and MMP-8 and a chest radiological score of cavitation and parenchymal damage. Respiratory epithelial cell-derived MMP-3 was suppressed by moxifloxacin, rifampicin, and azithromycin in a dose-dependent manner. Respiratory epithelial cell-derived MMP-1 was suppressed by moxifloxacin and azithromycin, whereas MMP-9 secretion was only decreased by moxifloxacin. In contrast, moxifloxacin and azithromycin both increased MMP-1 and -3 secretion from MRC-5 fibroblasts, demonstrating that the effects of these drugs are cell specific. Isoniazid did not affect MMP secretion. In conclusion, MMPs are elevated in bronchoalveolar lavage fluid from tuberculosis patients and correlate with parameters of tissue destruction. Antimycobacterial agents have a hitherto-undescribed immunomodulatory effect on MMP release by stromal cells.

摘要

肺结核的特征是肺细胞外基质广泛破坏和重塑。基质细胞衍生的基质金属蛋白酶(MMPs)参与了这一过程,可能是辅助免疫治疗的靶点。我们假设MMPs在肺结核患者的支气管肺泡灌洗液中升高,并且抗分枝杆菌药物可能对MMP分泌具有调节作用。与其他肺部疾病患者的支气管肺泡灌洗液相比,肺结核患者支气管肺泡灌洗液中MMP-1、-2、-3、-7、-8和-9的浓度升高。MMP-3、MMP-7和MMP-8与空洞形成和实质损害的胸部放射学评分呈正相关。莫西沙星、利福平和阿奇霉素以剂量依赖的方式抑制呼吸道上皮细胞衍生的MMP-3。莫西沙星和阿奇霉素抑制呼吸道上皮细胞衍生的MMP-1,而只有莫西沙星降低MMP-9的分泌。相反,莫西沙星和阿奇霉素均增加MRC-5成纤维细胞的MMP-1和-3分泌,表明这些药物的作用具有细胞特异性。异烟肼不影响MMP分泌。总之,MMPs在肺结核患者的支气管肺泡灌洗液中升高,并与组织破坏参数相关。抗分枝杆菌药物对基质细胞释放MMP具有迄今未描述的免疫调节作用。

相似文献

1
Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis.
Antimicrob Agents Chemother. 2014 Aug;58(8):4657-65. doi: 10.1128/AAC.02141-13. Epub 2014 Jun 2.
2
Interleukin-17 regulates matrix metalloproteinase activity in human pulmonary tuberculosis.
J Pathol. 2018 Mar;244(3):311-322. doi: 10.1002/path.5013. Epub 2018 Jan 18.
3
In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2004 Jan;48(1):340-3. doi: 10.1128/AAC.48.1.340-343.2004.
4
Breaking the Cycle: Matrix Metalloproteinase Inhibitors as an Alternative Approach in Managing Tuberculosis Pathogenesis and Progression.
ACS Infect Dis. 2024 Aug 9;10(8):2567-2583. doi: 10.1021/acsinfecdis.4c00385. Epub 2024 Jul 22.
5
Early Secretory Antigenic Target-6 Drives Matrix Metalloproteinase-10 Gene Expression and Secretion in Tuberculosis.
Am J Respir Cell Mol Biol. 2017 Feb;56(2):223-232. doi: 10.1165/rcmb.2016-0162OC.
6
Tuberculosis, pulmonary cavitation, and matrix metalloproteinases.
Am J Respir Crit Care Med. 2014 Jul 1;190(1):9-18. doi: 10.1164/rccm.201311-2106PP.
8
Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases.
Am J Respir Crit Care Med. 2012 May 1;185(9):989-97. doi: 10.1164/rccm.201110-1769OC. Epub 2012 Feb 16.
9
Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
J Chemother. 2006 Dec;18(6):617-23. doi: 10.1179/joc.2006.18.6.617.

引用本文的文献

1
"The effect of 48-weeks azithromycin therapy on levels of soluble biomarkers associated with HIV-associated chronic lung disease".
Int Immunopharmacol. 2023 Mar;116:109756. doi: 10.1016/j.intimp.2023.109756. Epub 2023 Jan 20.
2
Human Pulmonary Tuberculosis: Understanding the Immune Response in the Bronchoalveolar System.
Biomolecules. 2022 Aug 20;12(8):1148. doi: 10.3390/biom12081148.
3
Immunologic and imaging signatures in post tuberculosis lung disease.
Tuberculosis (Edinb). 2022 Sep;136:102244. doi: 10.1016/j.tube.2022.102244. Epub 2022 Aug 11.
4
Impact of Previous Pulmonary Tuberculosis on Chronic Obstructive Pulmonary Disease: Baseline Results from a Prospective Cohort Study.
Comb Chem High Throughput Screen. 2023;26(1):93-102. doi: 10.2174/1386207325666220406111435.
5
Pulmonary Functions and Inflammatory Biomarkers in Post-Pulmonary Tuberculosis Sequelae.
Tuberc Respir Dis (Seoul). 2022 Apr;85(2):175-184. doi: 10.4046/trd.2021.0127. Epub 2022 Mar 2.
6
Platelet Activation and the Immune Response to Tuberculosis.
Front Immunol. 2021 May 19;12:631696. doi: 10.3389/fimmu.2021.631696. eCollection 2021.
8
Host-directed therapy to combat mycobacterial infections.
Immunol Rev. 2021 May;301(1):62-83. doi: 10.1111/imr.12951. Epub 2021 Feb 9.
10
Selective toxicity of antibacterial agents-still a valid concept or do we miss chances and ignore risks?
Infection. 2021 Feb;49(1):29-56. doi: 10.1007/s15010-020-01536-y. Epub 2020 Dec 23.

本文引用的文献

1
Tendon Injury and Fluoroquinolone Use: A Systematic Review.
Drug Saf. 2013 Sep;36(9):709-21. doi: 10.1007/s40264-013-0089-8.
2
Induced sputum MMP-1, -3 & -8 concentrations during treatment of tuberculosis.
PLoS One. 2013 Apr 22;8(4):e61333. doi: 10.1371/journal.pone.0061333. Print 2013.
3
TB control in India--efforts, challenges and priorities.
J Indian Med Assoc. 2011 Dec;109(12):921-4, 928.
4
Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region.
PLoS One. 2013;8(2):e55299. doi: 10.1371/journal.pone.0055299. Epub 2013 Feb 4.
6
Totally drug resistant tuberculosis--a fact or myth?
Indian J Tuberc. 2012 Oct;59(4):190-3.
7
Trends in the annual risk of tuberculous infection in India.
Int J Tuberc Lung Dis. 2013 Mar;17(3):312-9. doi: 10.5588/ijtld.12.0330. Epub 2013 Jan 14.
8
Tuberculosis and poverty: why are the poor at greater risk in India?
PLoS One. 2012;7(11):e47533. doi: 10.1371/journal.pone.0047533. Epub 2012 Nov 19.
9
Status report on RNTCP.
Indian J Tuberc. 2012 Apr;59(2):107-11.
10
Tuberculosis--challenges and opportunities.
Indian J Tuberc. 2011 Oct;58(4):148-54.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验